Ovarian androgens but not estrogens correlate with the degree of systemic inflammation observed during controlled ovarian hyperstimulation

References

• Orvieto R, Voliovitch I, Fishman P, Ben-Rafael Z. Interleukin-2 and ovarian hyperstimulation syndrome – a pilot study. Hum Reprod 1995; 10: 24–27
   PubMed Web of Science ®Google Scholar
• Orvieto R, Ben-Rafael Z. Ovarian hyperstimulation syndrome: a new insight into an old enigma. J Soc Gynecol Investig 1998; 5: 110–113
   PubMedGoogle Scholar
• Orvieto R. Controlled ovarian hyperstimulation – an inflammatory state. J Soc Gynecol Investig 2004; 11: 424–426
   Google Scholar
• Orvieto R, Chen R, Ashkenazi J, Ben-Haroush A, Bar J, Fisch B. C-reactive protein levels in patients undergoing controlled ovarian hyperstimulation for in vitro fertilization cycle. Hum Reprod 2004; 19: 357–359
   PubMed Web of Science ®Google Scholar
• Sacks G P, Seyani L, Lavery S, Trew G. Maternal C-reactive protein levels are raised at 4 weeks' gestation. Hum Reprod 2004; 19: 1025–1030
   PubMed Web of Science ®Google Scholar
• Kemmann E, Tavakoli F, Shelden R M, Jones J R. Induction of ovulation with menotropins in women with polycystic ovary syndrome. Am J Obstet Gynecol 1981; 141: 58–64
   PubMedGoogle Scholar
• Kelly C CJ, Lyall H, Petrie J R, Gould G W, Connel J MC, Sattar N. Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 2002; 86: 2453–2455
   Google Scholar
• Mohlig M, Spranger J, Osterhoff M, Ristow M, Pfeiffer A FH, Schill T, Schlosser H W, Brabant G, Schofl C. The polycystic ovary syndrome per se is not associated with increased chronic inflammation. Eur J Endocrinol 2004; 150: 525–532
   PubMed Web of Science ®Google Scholar
• Orvieto R, Schwartz A, Bar Hava I, Abir R, Ashkenazi J, La-Marca A, Ben-Rafael Z. Controlled ovarian hyperstimulation – a state of endothelial activation. Am J Reprod Immunol 2000; 44: 257–260
   Google Scholar
• Orvieto R, Ben Rafael Z, Schwartz A, Abir R, Fisch B, La-Marca A, Bar-Hava I. Soluble l-selectin levels during controlled ovarian hyperstimulation. Gynecol Endocrinol 2001; 15: 29–33
   PubMedGoogle Scholar
• Fanchin R, de Ziegler D, Castracane V D, Taieb J, Olivennes F, Frydman R. Physiopathology of premature progesterone elevation. Fertil Steril 1995; 64: 796–801
   PubMedGoogle Scholar
• Fanchin R, Righini C, Olivennes F, Taieb J, de Ziegler D, Frydman R. Premature plasma progesterone and androgen elevation are not prevented by adrenal suppression in in vitro fertilization. Fertil Steril 1997; 67: 115–119
   PubMedGoogle Scholar
• Martin K A, Hornstein M D, Taylor A E, Hall J E, Barbieri R L. Exogenous gonadotropin stimulation is associated with increases in serum androgen levels in in-vitro fertilization – embryo transfer cycles. Fertil Steril 1997; 68: 1011–1016
   PubMed Web of Science ®Google Scholar
• Cedars M I, Surey E, Hamilton F, Lapolt P, Meldrum D R. Leuprolide acetate lowers circulating bioactive luteinizing hormone and testosterone concentrations during ovarian stimulation for oocyte retrieval. Fertil Steril 1990; 53: 627–631
   PubMed Web of Science ®Google Scholar
• Tadmor O P, Kleinman Y, Barr I, Gal M, Brooks B A, Diamant Y Z. Side effects of ovarian hyperstimulation: hormonal and lipid profile changes. Int J Fertil Menopausal Stud 1994; 39: 105–110
   PubMedGoogle Scholar
• Fanchin R, de Ziegler D, Taieb J, Olivennes F, Castracane D, Frydman R. Human chorionic gonadotropin administration does not increase plasma androgen levels in patients undergoing controlled ovarian hyperstimulation. Fertil Steril 2000; 73: 275–279
   PubMed Web of Science ®Google Scholar
• Slater C C, Chang L, Stanczyk F Z, Paulson R J. Altered balance between the 5α-reductase and aromatase pathways of androgen metabolism during controlled ovarian hyperstimulation with human menopausal gonadotropins. J Assist Reprod Genet 2001; 18: 527–533
   PubMedGoogle Scholar
• Casper R F, Erickson G F, Yen S S. Studies on the effect of gonadotropin-releasing hormone and its agonist on human luteal steroidogenesis in vitro. Fertil Steril 1984; 42: 39–43
   PubMedGoogle Scholar
• Castracane V D, Goldzieher J W. Plasma androgens during early pregnancy in the baboon (Papio cynocephalus). Fertil Steril 1983; 39: 553–559
   PubMedGoogle Scholar
• Almagor M, Hazav A, Yaffe H. The levels of C-reactive protein in women treated by IVF. Hum Reprod 2004; 19: 104–106
   PubMed Web of Science ®Google Scholar
• Orvieto R. Prediction of ovarian hyperstimulation syndrome. Challenging the estradiol mythos. Hum Reprod 2003; 18: 665–667
   PubMed Web of Science ®Google Scholar
• Liu P Y, Death A K, Handelsman D J. Androgens and cardiovascular disease. Endocr Rev 2003; 24: 313–340
   PubMed Web of Science ®Google Scholar
• Molinari C, Battaglia A, Grossini E, Mary D A, Vassanelli C, Vacca G. The effect of testosterone on regional blood flow in prepubertal anaesthetized pigs. J Physiol 2002; 543: 365–372
   Google Scholar
• Worboys S, Kotsopoulos D, Teede H, McGrath B, Davis S R. Evidence that parenteral testosterone therapy may improve endothelium-dependent and -independent vasodilation in postmenopausal women already receiving estrogen. J Clin Endocrinol Metab 2001; 86: 158–161
   PubMed Web of Science ®Google Scholar
• Szalai A J, van Ginkel F W, Dalrymple S A, Murray R, McGhee J R, Volanakis J E. Testosterone and IL-6 requirements for human C-reactive protein gene expression in transgenic mice. J Immunol 1998; 160: 5294–5299
   Google Scholar